Announcement • Aug 06
Syncom Formulations (India) Limited to Report Q1, 2027 Results on Aug 11, 2026 Syncom Formulations (India) Limited announced that they will report Q1, 2027 results on Aug 11, 2026 Reported Earnings • May 23
Full year 2026 earnings released: EPS: ₹0.81 (vs ₹0.53 in FY 2025) Full year 2026 results: EPS: ₹0.81 (up from ₹0.53 in FY 2025). Revenue: ₹5.21b (up 12% from FY 2025). Net income: ₹764.4m (up 55% from FY 2025). Profit margin: 15% (up from 11% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹12.25, the stock trades at a trailing P/E ratio of 16.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 88% over the past three years. Reported Earnings • Feb 14
Third quarter 2026 earnings released: EPS: ₹0.23 (vs ₹0.14 in 3Q 2025) Third quarter 2026 results: EPS: ₹0.23 (up from ₹0.14 in 3Q 2025). Revenue: ₹1.21b (down 5.4% from 3Q 2025). Net income: ₹189.1m (up 45% from 3Q 2025). Profit margin: 16% (up from 10% in 3Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth. Reported Earnings • Nov 13
Second quarter 2026 earnings released: EPS: ₹0.18 (vs ₹0.16 in 2Q 2025) Second quarter 2026 results: EPS: ₹0.18 (up from ₹0.16 in 2Q 2025). Revenue: ₹1.27b (up 24% from 2Q 2025). Net income: ₹166.0m (up 49% from 2Q 2025). Profit margin: 13% (up from 11% in 2Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 26% per year, which means it is significantly lagging earnings growth. Announcement • Oct 01
Syncom Formulations (India) Limited Approves Appointment of Shri Ankit Kedarmal as Executive Chairman Syncom Formulations (India) Limited at its AGM held on September 29, 2025, approved appointment of Shri Ankit Kedarmal as Executive Chairman and to approve the remuneration payable to him. Announcement • Aug 11
Syncom Formulations (India) Limited, Annual General Meeting, Sep 29, 2025 Syncom Formulations (India) Limited, Annual General Meeting, Sep 29, 2025, at 14:00 Indian Standard Time. Reported Earnings • Aug 09
First quarter 2026 earnings released: EPS: ₹0.21 (vs ₹0.11 in 1Q 2025) First quarter 2026 results: EPS: ₹0.21 (up from ₹0.11 in 1Q 2025). Revenue: ₹1.23b (up 41% from 1Q 2025). Net income: ₹157.5m (up 106% from 1Q 2025). Profit margin: 13% (up from 8.7% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 26% per year, which means it is significantly lagging earnings growth. Announcement • Aug 02
Syncom Formulations (India) Limited to Report Q1, 2026 Results on Aug 08, 2025 Syncom Formulations (India) Limited announced that they will report Q1, 2026 results on Aug 08, 2025 New Risk • May 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • May 21
Full year 2025 earnings released: EPS: ₹0.57 (vs ₹0.27 in FY 2024) Full year 2025 results: EPS: ₹0.57 (up from ₹0.27 in FY 2024). Revenue: ₹4.82b (up 83% from FY 2024). Net income: ₹494.3m (up 95% from FY 2024). Profit margin: 10% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 31% per year whereas the company’s share price has increased by 33% per year. Valuation Update With 7 Day Price Move • May 16
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹17.51, the stock trades at a trailing P/E ratio of 42x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 92% over the past three years. Announcement • May 13
Syncom Formulations (India) Limited to Report Q4, 2025 Results on May 19, 2025 Syncom Formulations (India) Limited announced that they will report Q4, 2025 results on May 19, 2025 Valuation Update With 7 Day Price Move • Mar 24
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹18.25, the stock trades at a trailing P/E ratio of 43.8x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 67% over the past three years. Valuation Update With 7 Day Price Move • Mar 10
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹17.12, the stock trades at a trailing P/E ratio of 41.1x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 32% over the past three years. Reported Earnings • Feb 11
Third quarter 2025 earnings released: EPS: ₹0.14 (vs ₹0.09 in 3Q 2024) Third quarter 2025 results: EPS: ₹0.14 (up from ₹0.09 in 3Q 2024). Revenue: ₹1.32b (up 102% from 3Q 2024). Net income: ₹130.0m (up 86% from 3Q 2024). Profit margin: 9.9% (in line with 3Q 2024). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Announcement • Feb 03
Syncom Formulations (India) Limited to Report Q3, 2025 Results on Feb 12, 2025 Syncom Formulations (India) Limited announced that they will report Q3, 2025 results on Feb 12, 2025 Reported Earnings • Nov 12
Second quarter 2025 earnings released: EPS: ₹0.16 (vs ₹0.08 in 2Q 2024) Second quarter 2025 results: EPS: ₹0.16 (up from ₹0.08 in 2Q 2024). Revenue: ₹1.06b (up 67% from 2Q 2024). Net income: ₹111.1m (up 71% from 2Q 2024). Profit margin: 10% (in line with 2Q 2024). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Nov 05
Syncom Formulations (India) Limited to Report Q2, 2025 Results on Nov 11, 2024 Syncom Formulations (India) Limited announced that they will report Q2, 2025 results on Nov 11, 2024 Valuation Update With 7 Day Price Move • Sep 19
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹22.24, the stock trades at a trailing P/E ratio of 73.2x. Average trailing P/E is 42x in the Pharmaceuticals industry in India. Total returns to shareholders of 204% over the past three years. Valuation Update With 7 Day Price Move • Aug 21
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₹19.10, the stock trades at a trailing P/E ratio of 62.9x. Average trailing P/E is 37x in the Pharmaceuticals industry in India. Total returns to shareholders of 190% over the past three years. Announcement • Aug 13
Syncom Formulations (India) Limited, Annual General Meeting, Sep 30, 2024 Syncom Formulations (India) Limited, Annual General Meeting, Sep 30, 2024, at 14:00 Indian Standard Time. Reported Earnings • Aug 13
First quarter 2025 earnings released: EPS: ₹0.11 (vs ₹0.07 in 1Q 2024) First quarter 2025 results: EPS: ₹0.11 (up from ₹0.07 in 1Q 2024). Revenue: ₹885.9m (up 48% from 1Q 2024). Net income: ₹76.3m (up 74% from 1Q 2024). Profit margin: 8.6% (up from 7.3% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 34% per year, which means it is well ahead of earnings. Announcement • Aug 02
Syncom Formulations (India) Limited to Report Q1, 2025 Results on Aug 12, 2024 Syncom Formulations (India) Limited announced that they will report Q1, 2025 results on Aug 12, 2024 Valuation Update With 7 Day Price Move • Jul 15
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹16.01, the stock trades at a trailing P/E ratio of 59.5x. Average trailing P/E is 35x in the Pharmaceuticals industry in India. Total returns to shareholders of 94% over the past three years. Reported Earnings • May 19
Full year 2024 earnings released: EPS: ₹0.34 (vs ₹0.22 in FY 2023) Full year 2024 results: EPS: ₹0.34 (up from ₹0.22 in FY 2023). Revenue: ₹2.77b (up 24% from FY 2023). Net income: ₹253.1m (up 26% from FY 2023). Profit margin: 9.1% (up from 8.9% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Apr 03
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹12.92, the stock trades at a trailing P/E ratio of 46x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 321% over the past three years. Announcement • Mar 29
Syncom Formulations (India) Limited Announces Board Changes Syncom Formulations (India) Limited announced that tenure completion of Shri Vinod Kumar Kabra, Shri Krishna Das Neema and Shri Praveen Jindal Independent Director(s) of the Company appointed w.e.f., 1 April, 2014 for a tenure of five (5) year and further were re-appointed w.e.f. 1 April, 2019 for further tenure of five (5) year in the category of Non-Executive Independent Directors of the company w.e.f. close of working hour of 31 March, 2024. Reported Earnings • Feb 15
Third quarter 2024 earnings released: EPS: ₹0.09 (vs ₹0.06 in 3Q 2023) Third quarter 2024 results: EPS: ₹0.09 (up from ₹0.06 in 3Q 2023). Revenue: ₹696.9m (up 22% from 3Q 2023). Net income: ₹70.0m (up 69% from 3Q 2023). Profit margin: 10.0% (up from 7.2% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 65% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Dec 26
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹14.13, the stock trades at a trailing P/E ratio of 56.5x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 326% over the past three years. Valuation Update With 7 Day Price Move • Nov 23
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to ₹12.65, the stock trades at a trailing P/E ratio of 50.6x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 538% over the past three years. Reported Earnings • Nov 11
Second quarter 2024 earnings released: EPS: ₹0.08 (vs ₹0.06 in 2Q 2023) Second quarter 2024 results: EPS: ₹0.08 (up from ₹0.06 in 2Q 2023). Revenue: ₹678.4m (up 25% from 2Q 2023). Net income: ₹65.1m (up 81% from 2Q 2023). Profit margin: 9.6% (up from 6.6% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 76% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Nov 09
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to ₹10.30, the stock trades at a trailing P/E ratio of 47x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 515% over the past three years. Announcement • Aug 15
Syncom Formulations (India) Limited, Annual General Meeting, Sep 26, 2023 Syncom Formulations (India) Limited, Annual General Meeting, Sep 26, 2023, at 15:00 Indian Standard Time. Reported Earnings • Aug 15
First quarter 2024 earnings released First quarter 2024 results: EPS: ₹0.07. Revenue: ₹617.1m (up 20% from 1Q 2023). Net income: ₹44.0m (up 14% from 1Q 2023). Profit margin: 7.1% (down from 7.5% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 71% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Aug 07
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹9.27, the stock trades at a trailing P/E ratio of 43.4x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 379% over the past three years. Announcement • Aug 04
Syncom Formulations (India) Limited to Report Q1, 2024 Results on Aug 14, 2023 Syncom Formulations (India) Limited announced that they will report Q1, 2024 results on Aug 14, 2023 Reported Earnings • Jun 02
Full year 2023 earnings released: EPS: ₹0.24 (vs ₹0.24 in FY 2022) Full year 2023 results: EPS: ₹0.24. Revenue: ₹2.39b (up 8.7% from FY 2022). Net income: ₹200.7m (up 1.4% from FY 2022). Profit margin: 8.4% (down from 9.0% in FY 2022). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Mar 28
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₹4.99, the stock trades at a trailing P/E ratio of 28.7x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 595% over the past three years. Reported Earnings • Feb 14
Third quarter 2023 earnings released: EPS: ₹0.06 (vs ₹0.07 in 3Q 2022) Third quarter 2023 results: EPS: ₹0.06. Revenue: ₹593.6m (up 3.7% from 3Q 2022). Net income: ₹41.4m (up 3.3% from 3Q 2022). Profit margin: 7.0% (in line with 3Q 2022). Announcement • Feb 02
Syncom Formulations (India) Limited to Report Q3, 2023 Results on Feb 13, 2023 Syncom Formulations (India) Limited announced that they will report Q3, 2023 results on Feb 13, 2023 Valuation Update With 7 Day Price Move • Dec 23
Investor sentiment improved over the past week After last week's 24% share price gain to ₹9.74, the stock trades at a trailing P/E ratio of 56.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,221% over the past three years. Reported Earnings • Nov 19
Second quarter 2023 earnings released: EPS: ₹0.06 (vs ₹0.06 in 2Q 2022) Second quarter 2023 results: EPS: ₹0.06 (in line with 2Q 2022). Revenue: ₹544.9m (up 2.9% from 2Q 2022). Net income: ₹35.9m (down 36% from 2Q 2022). Profit margin: 6.6% (down from 11% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 128% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Nov 16
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. No experienced directors. 6 highly experienced directors. Additional Non-Executive Independent Woman Director Ruchi Jindal was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Sep 20
Syncom Formulations (India) Limited Approves the Declaration of Dividend for the Financial Year Ended 31 March 2022 Syncom Formulations (India) Limited at its AGM held on September 19, 2022, approved the declaration of dividend on equity shares INR 0.03 (3.00%) on the equity share of INR 1 each of the Company for the Financial Year ended 31 March, 2022 by way of an Ordinary Resolution. Upcoming Dividend • Sep 02
Upcoming dividend of ₹0.03 per share Eligible shareholders must have bought the stock before 09 September 2022. Payment date: 19 October 2022. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.6%). Lower than average of industry peers (1.0%). Reported Earnings • Aug 18
First quarter 2023 earnings released: EPS: ₹0.03 (vs ₹0.08 in 1Q 2022) First quarter 2023 results: EPS: ₹0.03 (down from ₹0.08 in 1Q 2022). Revenue: ₹543.8m (up 6.1% from 1Q 2022). Net income: ₹38.7m (down 28% from 1Q 2022). Profit margin: 7.1% (down from 11% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 126% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Aug 16
Syncom Formulations (India) Limited, Annual General Meeting, Sep 19, 2022 Syncom Formulations (India) Limited, Annual General Meeting, Sep 19, 2022, at 14:00 Indian Standard Time. Location: 7, Niraj Industrial Estate. Off Mahakali Caves Road Andhcri (East) Mumbai India Agenda: To receive, consider, approve and adopt the Standalone Audited Financial statements containing the balance Sheet as at 31st March, 2022, the Statement of Profit & Loss and Cash Flow and Changes in Equity. for the financial year ended 31st March, 2022 and the Reports of the Boards and Auditors thereon as on that date; to declare dividend on equity shares of the Company for the Financial Year ended March 31, 2022; to appoint a director; to consider re-appointment of M/s. Sanjay Mehta & Associates, Chartered Accountants as the Statutory Auditors of the Company; to ratify the remuneration of Cost Auditor of the company for the year 2022-23; and to consider other related matters. Valuation Update With 7 Day Price Move • Jul 21
Investor sentiment improved over the past week After last week's 20% share price gain to ₹9.58, the stock trades at a trailing P/E ratio of 45.5x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,083% over the past three years. Announcement • Jun 29
Syncom Formulations (India) Limited Appoints Ruchi Jindal as an Additional Director Syncom Formulations (India) Limited at its Board Meeting held on June 28, 2022, the Board has upon the recommendation of the Nomination and Remuneration Committee has appointed Mrs. Ruchi Jindal as an Additional Director (Woman Independent Director) on the Board of Directors till the date of next General Meeting or within 3 months whichever may be earlier and consequently there is a change in Directors pursuant to such appointment. Mrs. Ruchi Jindal is' a chartered accountants and has working experience of more than five years in Baidyanath Group of Companies and has managed finance, Accounts and Internal Management. She is currently owning the Central India's Biggest and top l0 in e- Commerce platform "Premium Bike Accessories Showroom". Buying Opportunity • Jun 20
Now 25% undervalued after recent price drop Over the last 90 days, the stock is down 43%. The fair value is estimated to be ₹8.46, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.8% over the last 3 years. Earnings per share has grown by 31%. Valuation Update With 7 Day Price Move • Jun 16
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₹7.32, the stock trades at a trailing P/E ratio of 34.8x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 732% over the past three years. Reported Earnings • May 24
Full year 2022 earnings released: EPS: ₹0.26 (vs ₹0.38 in FY 2021) Full year 2022 results: EPS: ₹0.26 (down from ₹0.38 in FY 2021). Revenue: ₹2.20b (down 10% from FY 2021). Net income: ₹197.9m (down 32% from FY 2021). Profit margin: 9.0% (down from 12% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 100% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • May 10
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₹9.09, the stock trades at a trailing P/E ratio of 35.7x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 857% over the past three years. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 5 highly experienced directors. Whole Time Director Rinki Bankda was the last director to join the board, commencing their role in 2014. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment improved over the past week After last week's 17% share price gain to ₹12.47, the stock trades at a trailing P/E ratio of 48.9x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,013% over the past three years. Valuation Update With 7 Day Price Move • Mar 14
Investor sentiment improved over the past week After last week's 25% share price gain to ₹13.00, the stock trades at a trailing P/E ratio of 51x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,061% over the past three years. Reported Earnings • Feb 17
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹0.07 (down from ₹0.13 in 3Q 2021). Revenue: ₹572.3m (down 32% from 3Q 2021). Net income: ₹40.1m (down 60% from 3Q 2021). Profit margin: 7.0% (down from 12% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has increased by 128% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Feb 17
Investor sentiment deteriorated over the past week After last week's 20% share price decline to ₹11.75, the stock trades at a trailing P/E ratio of 34.8x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,087% over the past three years. Valuation Update With 7 Day Price Move • Dec 29
Investor sentiment improved over the past week After last week's 21% share price gain to ₹11.40, the stock trades at a trailing P/E ratio of 33.8x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,153% over the past three years. Valuation Update With 7 Day Price Move • Oct 07
Investor sentiment improved over the past week After last week's 32% share price gain to ₹9.34, the stock trades at a trailing P/E ratio of 24.5x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,082% over the past three years. Valuation Update With 7 Day Price Move • Sep 22
Investor sentiment improved over the past week After last week's 17% share price gain to ₹6.99, the stock trades at a trailing P/E ratio of 17.5x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 636% over the past three years. Valuation Update With 7 Day Price Move • Aug 20
Investor sentiment deteriorated over the past week After last week's 18% share price decline to ₹5.97, the stock trades at a trailing P/E ratio of 15.7x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 463% over the past three years. Valuation Update With 7 Day Price Move • Jul 29
Investor sentiment deteriorated over the past week After last week's 18% share price decline to ₹7.02, the stock trades at a trailing P/E ratio of 18.5x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 588% over the past three years. Reported Earnings • Jul 04
Full year 2021 earnings released: EPS ₹0.38 (vs ₹0.17 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹2.45b (up 19% from FY 2020). Net income: ₹291.7m (up 105% from FY 2020). Profit margin: 12% (up from 6.9% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has increased by 96% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Apr 14
Investor sentiment improved over the past week After last week's 21% share price gain to ₹3.72, the stock trades at a trailing P/E ratio of 11.5x. Average trailing P/E is 19x in the Pharmaceuticals industry in India. Total returns to shareholders of 180% over the past three years. Is New 90 Day High Low • Mar 14
New 90-day low: ₹3.09 The company is down 3.0% from its price of ₹3.18 on 14 December 2020. The Indian market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. Reported Earnings • Feb 17
Third quarter 2021 earnings released: EPS ₹0.13 (vs ₹0.04 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹841.7m (up 61% from 3Q 2020). Net income: ₹100.2m (up 186% from 3Q 2020). Profit margin: 12% (up from 6.7% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth. Announcement • Feb 04
Syncom Formulations (India) Limited to Report Q3, 2021 Results on Feb 12, 2021 Syncom Formulations (India) Limited announced that they will report Q3, 2021 results on Feb 12, 2021 Is New 90 Day High Low • Jan 06
New 90-day high: ₹3.72 The company is up 140% from its price of ₹1.55 on 08 October 2020. The Indian market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 8.0% over the same period. Announcement • Dec 20
Syncom Formulations (India) Limited announced that it expects to receive INR 100.787496 million in funding Syncom Formulations (India) Limited (BSE:524470) announced a private placement of up to 159,347,820 prepaid warrants at INR 0.6325 per warrant for gross proceeds of up to INR 100,787,496.15 on December 18, 2020. The round will include participation from promoter and promoter group on preferential basis. The company will receive 25% of the total amount, which is INR 100,787,496.15 as upfront payment at the time of allotment of warrants and the remaining 75% will be received within 18 months. The warrants will be exercisable into common shares at INR 1.8975 per share in one or more tranches within a period of 18 months. Each common share to be issued will have a par value of INR 1. The transaction is subject to shareholder’s approval in extra ordinary general meeting to be held on January 12, 2021. The board of directors of the company approved the transaction. Valuation Update With 7 Day Price Move • Dec 02
Market bids up stock over the past week After last week's 20% share price gain to ₹2.28, the stock is trading at a trailing P/E ratio of 12.4x, up from the previous P/E ratio of 10.4x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 14%. Is New 90 Day High Low • Nov 17
New 90-day high: ₹1.93 The company is up 4.0% from its price of ₹1.85 on 19 August 2020. The Indian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 1.0% over the same period. Valuation Update With 7 Day Price Move • Nov 13
Market bids up stock over the past week After last week's 21% share price gain to ₹1.76, the stock is trading at a trailing P/E ratio of 9.6x, up from the previous P/E ratio of 8x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 7.3%. Is New 90 Day High Low • Oct 15
New 90-day low: ₹1.42 The company is down 14% from its price of ₹1.66 on 17 July 2020. The Indian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 14% over the same period. Announcement • Jul 05
Syncom Formulations (India) Limited to Report Q4, 2020 Results on Jun 30, 2020 Syncom Formulations (India) Limited announced that they will report Q4, 2020 results on Jun 30, 2020